Trial Profile
An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Pharmacodynamics
- Sponsors Bavarian Nordic
- 12 Nov 2022 Pooled analysis assessing immunological persistence and booster effects published in the Journal of Infectious Diseases
- 24 Mar 2012 Planned number of patients is 150 as reported by European Clinical Trials Database record.
- 21 May 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.